
Please try another search
On Mar 9, we issued an updated research report on IDEXX Laboratories, Inc. (NASDAQ:IDXX) . The company witnesses strong organic revenue growth in the international business. Additionally, its companion animal market fundamentals remain solid with tremendous global runway for growth. The stock carries a Zacks Rank #2 (Buy).
Also, this leading molecular diagnostic company has been outperforming its industry in the past three months. The stock has rallied 28.4% compared with 11% gain of the industry.
Meanwhile, IDEXX continues to demonstrate solid growth globally with strong international expansion. In fourth-quarter 2017, the company witnessed double-digit organic revenue growth in the international business. This upside was owing to continued consumable revenue gains supported by Catalyst instrument base and average testing utilization.
In international markets, the company witnessed considerable organic lab revenue gains supported by positive customer response to SDMA as well as significant growth in rapid assay sales. In addition, management experienced steady growth in reference labs led by consistent gains in Europe.
Furthermore, CAG organic revenue growth in low-double digits on strong VetLab consumables and CAG Diagnostics recurring organic revenue growth is impressive. We are also optimistic about the company’s expanding premium instrument base in the United States and international markets, including growth in competitive instrument placements, increasing utilization and continued customer retention.
Moving ahead, we expect the company to gain from the commercial launch of Catalyst SDMA Test in North America in January. IDEXX too entered into a global agreement with a diagnostic company — Applied BioCode — in the same month.
Moreover, IDEXX has a strong cash balance that allows it to carry out share repurchases. Nevertheless, its high dependence on third-party distributors and intense competition continue to pose threats.
Other Stocks to Consider
Some other top-ranked stocks in the broader medical sector are PerkinElmer (NYSE:PKI) , Bio-Rad Laboratories (NYSE:BIO) and athenahealth, Inc. (NASDAQ:ATHN) .
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
Bio-Rad Laboratories sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
The fortune of Nvidia (NASDAQ:NVDA) is closely tied to Big Tech hyperscalers. Although the AI/GPU designer didn’t name its largest clients in the latest 10-K filing on Wednesday,...
In a market fraught with uncertainty, investors often seek refuge in defensive-minded stocks that offer stability and resilience. Two such stalwarts, Johnson & Johnson and...
The United States is the largest exporter of liquefied natural gas (LNG), having surpassed Australia and Qatar in 2023. The United States exports an estimated 12.5 billion cubic...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.